Drug Profile
Moxetumomab pasudotox - AstraZeneca
Alternative Names: CAT-8015; CD22-directed immunotoxin; GCR-8015; HA22; LUMOXITI; Lumoxiti; Moxetumomab pasudotox-tdfkLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Developer AstraZeneca; M. D. Anderson Cancer Center; MedImmune; National Cancer Institute (USA)
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Peptide elongation factor 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hairy cell leukaemia
- Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 08 Feb 2021 Registered for Hairy cell leukaemia (Second-line therapy or greater) in European Union, Norway, Liechtenstein, Iceland (IV)
- 01 Jan 2021 The CHMP recommends approval of moxetumomab pasudotox for hairy cell leukaemia (Late-stage disease, Second-line therapy or greater) in the EU
- 11 Dec 2020 Innate Pharma plans to return the US and EU commercialisation rights of moxetumomab pasudotox-tdfk to AstraZeneca in 2021